Interesting ImagesHypoxia and Amino Acid Imaging of High-Grade Glioma 18F-FAZA PET/CT and 11C-Methionine PET/MRIMapelli, Paola MD*,†; Fallanca, Federico MD†; Scifo, Paola PhD†; Barbera, Maurizio MD‡; Castellano, Antonella MD*,‡; Bettinardi, Valentino MSc†; Incerti, Elena MSc†; Gianolli, Luigi MD†; Anzalone, Nicoletta MD*,‡; Picchio, Maria MD*,†Author Information From the *Vita-Salute San Raffaele University †Nuclear Medicine Department ‡Neuroradiology Unit and CERMAC, IRCCS San Raffaele Scientific Institute, Milan, Italy. Received for publication September 18, 2019; revision accepted February 16, 2020. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from the participant included in the study. Conflicts of interest and sources of funding: M.P. received a GE Healthcare travel meeting support not related to the work. The other authors have no conflicts of interest to declare. Correspondence to: Maria Picchio, MD, Vita-Salute San Raffaele University, Department of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy. E-mail: email@example.com. Online date: April 23, 2020 Clinical Nuclear Medicine: June 2020 - Volume 45 - Issue 6 - p e290-e293 doi: 10.1097/RLU.0000000000003028 Buy Metrics Abstract In the present case, we report the first experience of a patient with high-grade glioma who underwent dual 18F-FAZA PET/CT imaging for intratumoral hypoxia assessment, before treatment, and for therapy monitoring in the suspicious of recurrence, as part of a clinical research protocol. In addition, despite the diagnosis of glioblastoma, the patient at 3 years from diagnosis was alive and underwent 11C-methionine simultaneous PET/MRI for disease monitoring after treatment, showing stability of disease. The multitracer capability of PET in assessing different and complementary metabolic features along with the use of a last-generation scanner as PET/MRI in brain oncology are here enlighten. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.